Minghui’s MHB088C will soon start phase 3 in China.
ApexOnco Front Page
Recent articles
After earlier masked probody setbacks, CytomX surprises with CX-2051.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
The same trial that sent Summit up 272% sees the stock crash 36%.
